Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Peter Buhl Jensen, CEO in Oncology Venture buys shares in the Company

Regulatory

Correction new weekday: Oncology Venture: Notice to Convene Extraordinary General Meeting

Regulatory

Oncology Venture: Notice to Convene Extraordinary General Meeting

Regulatory

Oncology Venture A/S: Publication of financial report Q3 2018

Regulatory

Oncology Venture enters into financing agreement

Non-Regulatory

OV – Update Regarding Participation at Investor Events in Q4 2018

Regulatory

OV – Clinical up-date

Regulatory

OV – OV increases its share capital due to warrant exercise

Non-Regulatory

OV – Oncology Venture requests meeting with FDA to discuss pathway for LiPlaCis and DRP approval in the US

Regulatory

OV – First prostate cancer patient included in Oncology Venture’s Phase 2 study of Irofulven for personalized treatment

Non-Regulatory

OV: Oncology Venture to Participate at Upcoming Investor Events in Q4 2018

Regulatory

OV – Oncology Venture receives authority clearance to expand an ongoing Phase 2 study of LiPlaCis by inclusion of prostate cancer patients

Non-Regulatory

OV – Oncology Venture’s PARP inhibitor Evaluation for Childhood Cancer Passes First Feasibility Steps

Regulatory

OV – Updated LiPlaCis data positions LiPlaCis and its DRP for an FDA Breakthrough Therapy designation application for breast cancer

Non-Regulatory

OV – Oncology Venture to present at InvestorDagen in Copenhagen and invites Investors to join

Non-Regulatory

MPI – DRP predicts drug efficacy in breast cancer patients. New study on cornerstone drug epirubicin published in “Breast Cancer Research and Treatment”

Non-Regulatory

MPI: MPI has now executed transfer of the last tranche of the Oncology Venture shares sold during May

Non-Regulatory

MPI – Oncology Venture looks forward to publishing a clinical update on July 2

Non-Regulatory

MPI – MPI and Oncology Venture are merging – here are answers to When, How and What

Regulatory

MPI – Clinical data on PARP inhibitor 2X-121 and DRP response prediction validation to be presented on the world’s largest cancer congress ASCO 2018